Drug class in one race
FLT3 drugs for Acute Myeloid Leukemia
6 tracked FLT3 drugs in the Acute Myeloid Leukemia race. The class explanation lives on the FLT3 page; the full indication pipeline across every mechanism is on the Acute Myeloid Leukemia page.
2 approved / phase 42 Phase 32 Phase 1
Head-to-head evidence: BMF-500 vs Gilteritinib · BMF-500 vs Quizartinib · Clifutinib Besylate vs Gilteritinib · Clifutinib Besylate vs Quizartinib · Gilteritinib vs Quizartinib · Gilteritinib vs XY0206